Clinical trials: Ticagrelor
Coronary Artery Disease
Cangrelor Ticagrelor Transition Study
To demonstrate that patients treated with cangrelor can be directly switched to oral ticagrelor and that patients treated with ticagrelor can be switched to cangrelor without a significant decrease in the extent of inhibition of…
- Trial name
- NCT01766466
- Testing
- cangrelor, Ticagrelor
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Medicines Company
Coronary Heart Disease
A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient
Study in Vietnamese Patients with Coronary Heart Disease to investigate safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel
- Trial name
- NCT01757262
- Testing
- 90 mg Ticagrelor, 75mg Clopidogrel
- Sponsor
- AstraZeneca
Drug Effect Disorder, Platelet Procoagulant Activity Deficiency
the Effect Between Platelet Reactivation and Antiplatelet Drugs
Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes.
- Trial name
- NCT02198053
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Anzhen Hospital
Platelet Reactivity
Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients with coronary artery disease, but these benefits come at the expense of increased risk of bleeding when compared with…
- Trial name
- NCT04001894
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Cardiovascular Disease, Interventional Cardiology
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
The purpose of this study is to compare the use of ticagrelor alone versus ticagrelor and aspirin together. Both ticagrelor and aspirin stop platelets from sticking together and forming a blood clot that could block blood flow to…
- Trial name
- TWILIGHT (NCT02270242)
- Testing
- Aspirin, ticagrelor
- Where
- United States
- Volunteers
- 9,006 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronary Artery Disease
Impact of Ticagrelor Re-load on Pharmacodynamic Profiles
Platelets are parts of your blood that stick together to help form a clot. The stickier your platelets are, the greater your chance of having a heart attack. A clot in the wrong place can lead to a heart attack or stroke.
- Trial name
- NCT01731041
- Testing
- Ticagrelor 180mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida
Symptomatic Aortic Stenosis
Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation
The narrowing of the aortic valve, which prevents blood from reaching the entire body correctly is a common disease in our environment.
- Trial name
- REACTIC-TAVI (NCT04331145)
- Testing
- Ticagrelor 60mg
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Andres Iñiguez Romo
Coronary Artery Disease, Coronary Artery Bypass Grafting
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting trial (TOP-CABG trial) is a multicenter, randomized, double-blind, non-inferiority, parallel controlled trial.
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Dual Antiplatelet Therapy, Bleeding
- Trial name
- TOP-CABG (NCT05380063)
- Testing
- De-escalated Dual Antiplatelet Therapy, Dual Antiplatelet Therapy
- Where
- China
- Volunteers
- 2,300 people
- Sponsor
- China National Center for Cardiovascular Diseases
Acute Coronary Syndrome
Brilinta DaYu Study
A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the incidence of major cardiovascular events of ticagrelor in Chinese patients with acute coronary syndrome
- Trial name
- DaYu (NCT01870921)
- Testing
- Ticagrelor
- Where
- 39 sites in China
- Volunteers
- 2,004 people
- Sponsor
- AstraZeneca
Cerebrovascular Accident, Cerebrovascular Accident, Acute
Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke
Cerebrovascular disease is the main cause of death and severe long-term disability worldwide. Antiplatelet drugs are the main drugs for ischemic stroke and TIA.
- Trial name
- NCT04962451
- Testing
- ticagrelor + ASA
- Where
- China
- Volunteers
- 13,000 people
- Sponsor
- Peking University Third Hospital
STEMI, STEMI - ST Elevation Myocardial Infarction
The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor
Fast and accurate platelet inhibition is an important therapeutic goal in the acute treatment of patients with ST-segment elevation myocardial infarction (STEMI).
- Trial name
- ON-TIME 3 (NCT03400267)
- Testing
- Paracetamol, Fentanyl
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- A.H. Tavenier
Acute Myocardial Infarction
Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Prospective, randomized, open-label, single-center, investigator-initiated trial, including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) within 12…
- Trial name
- PERSEUS (NCT02531165)
- Testing
- Fentanyl, Morphine, Ticagrelor
- Where
- Switzerland
- Volunteers
- 38 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Unstable Angina Pectoris
Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study
The purpose of this study is to evaluate the differences in pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite depending on the strategy of the drug administration in patients with unstable angina…
- Trial name
- NCT02612116
- Testing
- Pulverized ticagrelor sublingually, Pulverized ticagrelor orally, Integral ticagrelor
- Where
- Poland
- Volunteers
- 49 people
- Sponsor
- Collegium Medicum w Bydgoszczy
LOVASTATIN/TICAGRELOR [VA Drug Interaction]
The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI
The purpose of this study is to determine ticagrelor combining with low molecular weight heparin is effective and safe during PCI or not.
- Trial name
- NCT02658838
- Testing
- Ticagrelor, full amount low molecular weight heparin, half amount low molecular weight heparin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing Anzhen Hospital
Cardiac Arrest, Postresuscitation Syndrome
Antiplatelet Therapy After Cardiac Arrest
There is growing evidence that standard dual antiplatelet therapy with acetylsalicylic acid (ASA) and clopidogrel is not as effective in the setting of therapeutic hypothermia after cardiac arrest as in normothermic patients.
- Conditions
- Cardiac Arrest, Postresuscitation Syndrome, Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)
- Trial name
- NCT02224274
- Testing
- Clopidogrel, Ticagrelor
- Where
- Slovenia
- Volunteers
- 57 people
- Sponsor
- University Medical Centre Ljubljana
Non-ST-elevation Acute Coronary Syndrome, Unstable Angina
Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly
A randomized controlled, open label, multicenter trial with 1000 patients aged 70 years and older, presenting with Non-ST-elevation acute coronary syndrome.
- Conditions
- Non-ST-elevation Acute Coronary Syndrome, Unstable Angina, Non-ST-elevation Myocardial Infarction
- Trial name
- POPular AGE (NCT02317198)
- Testing
- Clopidogrel, Ticagrelor or Prasugrel
- Where
- Netherlands
- Volunteers
- 1,011 people
- Sponsor
- St. Antonius Hospital
Non ST-elevation Myocardial Infarction
Brilinta Taiwan Post Approval Safety Study
A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the…
- Trial name
- NCT02406248
- Testing
- Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
- Where
- 13 sites in Taiwan
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Ticagrelor, Pharmacokinetics
Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Ticagrelor
It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%.
- Conditions
- Ticagrelor, Pharmacokinetics, Pharmacodynamics, Pharmacogenomics
- Trial name
- NCT03161002
- Testing
- detection of genotype
- Where
- 7 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Cui Yimin
Coronary Artery Disease, Acute Coronary Syndrome
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class cyclopentyltriazolopyrimidine (CPTP).
- Trial name
- SWAP3 (NCT02016170)
- Testing
- Ticagrelor 180mg, Prasugrel 10mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Florida
Non ST Segment Elevation Acute Coronary Syndrome, Chronic Kidney Disease
COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS
Ticagrelor, a new P2Y12 receptor antagonist, achieve faster, consistent and higher platelet inhibition than clopidogrel, which was considered more noticeable in patients with ACS combining chronic kidney disease(CKD).
- Trial name
- OPT-CKD (NCT02578537)
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenyang Northern Hospital